Maxomat ®, biosynthetic growth hormone    (DrugBank: Growth hormone)

1 disease
IDDisease name (Link within this page)Number of trials
195Noonan syndrome1

195. Noonan syndrome    [ 14 clinical trials,   15 drugs,   (DrugBank: 5 drugs),   2 drug target genes,   9 drug target pathways]
Searched query = "Noonan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 14 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00452725
(ClinicalTrials.gov)
October 199723/3/2007Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's SyndromeEffect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's SyndromeNoonan SyndromeDrug: MAXOMAT ®, biosynthetic growth hormoneSanofiNULLCompleted3 Years15 YearsBoth36Phase 3France